Canaccord Genuity Group Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $140.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price trimmed by Canaccord Genuity Group from $141.00 to $140.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also issued reports on the company. Stifel Nicolaus set a $131.00 price target on Rhythm Pharmaceuticals in a report on Thursday, February 26th. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. HC Wainwright reduced their target price on shares of Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating for the company in a research note on Monday. The Goldman Sachs Group boosted their target price on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, Royal Bank Of Canada assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Wednesday, February 18th. They set an “outperform” rating and a $145.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.07.

Rhythm Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:RYTM opened at $91.00 on Monday. The firm has a fifty day moving average of $102.65 and a two-hundred day moving average of $103.42. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20. The firm has a market capitalization of $6.21 billion, a P/E ratio of -29.26 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The business had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. During the same period last year, the company earned ($0.72) earnings per share. Rhythm Pharmaceuticals’s quarterly revenue was up 36.9% compared to the same quarter last year. Equities research analysts expect that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares in the company, valued at $11,190,445.12. This trade represents a 3.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the sale, the insider owned 20,814 shares of the company’s stock, valued at $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,003 shares of company stock worth $2,589,015 over the last quarter. 6.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Rhythm Pharmaceuticals by 39.2% during the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock worth $504,589,000 after buying an additional 1,407,313 shares during the last quarter. RA Capital Management L.P. increased its position in Rhythm Pharmaceuticals by 17.3% during the fourth quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after acquiring an additional 985,478 shares during the period. Alliancebernstein L.P. raised its stake in Rhythm Pharmaceuticals by 1,493.8% during the 3rd quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after purchasing an additional 918,212 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Rhythm Pharmaceuticals by 445.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 783,559 shares of the company’s stock valued at $49,513,000 after purchasing an additional 639,919 shares during the last quarter. Finally, Capital Research Global Investors bought a new stake in Rhythm Pharmaceuticals in the 3rd quarter valued at $60,417,000.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $140, signaling stronger upside expectations from that shop and likely supporting buying interest. Canaccord raises PT to $140
• Neutral Sentiment: H.C. Wainwright reaffirmed a “Buy” stance and set a $110 target, keeping institutional support for the stock even after adjusting assumptions; that helps sentiment but is less bullish than Canaccord’s view. H.C. Wainwright price target cut to $110
• Negative Sentiment: H.C. Wainwright cut near-term EPS forecasts sharply — trimming FY2026 and multiple quarterly estimates and pushing meaningful profitability into 2027 (they still model positive EPS in FY2027). Those downgraded near-term earnings projections increase execution risk and explain some downward pressure/volatility despite the maintained Buy rating.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.